Clinical trials: Relapsed Cancer
Lymphoblastic Leukemia, Acute
Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia
This study will determine the maximum tolerated dose of genetically modified natural killer (NK) cells in research participants with relapsed or refractory B-lineage acute lymphoblastic leukemia (ALL).
- Trial name
- NCT00995137
- Testing
- NK Cell Infusion
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- St. Jude Children's Research Hospital
B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
This phase II trial studies giving rituximab before and after a donor peripheral blood stem cell transplant in patients with B-cell lymphoma that does not respond to treatment (refractory) or has come back after a period of…
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Childhood Burkitt Lymphoma
- Trial name
- NCT00867529
- Testing
- rituximab, peripheral blood stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Fred Hutchinson Cancer Center
Relapsed/Refractory B-cell ALL
CART-19 Cells For R/R B-ALL
There are limited treatment options for relapse/refractory B-cell acute lymphoblastic leukemia(ALL). However,CART-19 cells has emerged as a powerful targeted immunotherapy for highly refractory CD19+ acute lymphoblastic leukemia…
- Trial name
- CCFRRBA (NCT03391739)
- Testing
- CART-19 cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fujian Medical University
Ewing Sarcoma, Rhabdomyosarcoma
Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Investigators are testing new experimental drug combinations such as the combination of vorinostat, vincristine, irinotecan, and temozolomide in the hopes of finding a drug that may be effective against tumors that have come back…
- Conditions
- Ewing Sarcoma, Rhabdomyosarcoma, Wilms Tumor, Neuroblastoma
- Trial name
- NYMC195 (NCT04308330)
- Testing
- Vorinostat
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- New York Medical College
Multiple Myeloma
PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma
Prospective multicenter phase 2 study using PAD and Thal/Dex combination sequentially.
- Trial name
- NCT00319865
- Testing
- Velcade, Thalidomide, Adriamycin
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Korean Multiple Myeloma Working Party
Acute Lymphoblastic Leukemia
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia
This study is a single arm clinical study to observe the safety ，dose tolerance and pharmacokinetic characteristics of CAR NK-CD19 in patients with recurrent or refractory CD19 positive acute lymphoblastic leukemia, and…
- Trial name
- NCT05563545
- Testing
- CAR-NK-CD19 Cells
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
Lymphoma, Non-Hodgkin
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
The purpose of this study is to confirm that the pharmacokinetics of ibrutinib in pediatric participants is consistent with that in adults (part 1) and to assess efficacy (event-free survival [EFS]) of ibrutinib in combination…
- Trial name
- NCT02703272
- Testing
- Ibrutinib, Rituximab, Ifosfamide
- Where
- 76 sites in United States, Belgium and 18 more
- Volunteers
- 72 people
- Sponsor
- Janssen Research & Development, LLC
Lymphoma, Leukemia
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
This research is being done to learn more about reduced-intensity bone marrow transplantation (BMT), also known as a "mini" transplant for patients with blood cancers, using bone marrow from a relative.
- Conditions
- Lymphoma, Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01135329
- Testing
- Fludarabine, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse
Study of Anti-CD22 CAR-T Cells Treating Leukemia Children
The investigators will conduct a phase II clinical trial of autologous humanized anti-CD22 chimeric antigen receptor T cells treating refractory or relapsed B acute lymphoblastic leukemia children in Beijing Boren Hospital.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT04340167
- Testing
- Autologous humanized anti-CD22 chimeric antigen receptor T cells
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Beijing Boren Hospital
B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia
CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia
Brief Summary: Cluster of differentiation 19 (CD19) is expressed on B cells. CD19+ tumor cells in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia can be targeted using T cells expressing CD19-specific chimeric…
- Trial name
- NCT06027957
- Testing
- anti-CD19 CAR T-cells
- Where
- Vietnam
- Volunteers
- 18 people
- Sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
Relapsed/Refractory Lymphoid Malignancies, Relapsed/Refractory Myeloid Malignancies
Expanded Access to Venetoclax
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Trial name
- NCT03123029
- Testing
- Venetoclax
- Sponsor
- AbbVie
Leukemia, Acute Myeloid
Epigenetic Reprogramming in Relapse AML
Successful treatment for children and young adults with relapsed acute myeloid leukemia (AML) continues to be a significant challenge.
- Trial name
- NCT02412475
- Testing
- Decitabine, Vorinostat, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Michael Burke
Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia
DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia
This laboratory study is looking at DNA in tumor tissue samples from young patients with acute lymphoblastic leukemia. DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment
- Trial name
- NCT00897507
- Testing
- Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 520 people
- Sponsor
- Children's Oncology Group
Bladder Cancer, Urethral Cancer
Combination Chemotherapy in Treating Patients With Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003701
- Testing
- carboplatin, cisplatin, doxorubicin hydrochloride
- Where
- 13 sites in United States
- Volunteers
- 490 people
- Sponsor
- Eastern Cooperative Oncology Group
Relapse Leukemia, Refractory Leukemia
Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
CD19 CAR-T has been widely developed in patients with R/R ALL and has also been generally recognized by the industry. In 2017, the U.S. FDA approved Novartis's CD 19 CAR-T product Kymriah for the treatment of R/R ALL.
- Trial name
- CAR-T (NCT05164042)
- Testing
- Allogeneic CD19 CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen University General Hospital
Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial
This phase I trial investigates the side effects and determines the best dose of an immune cell therapy called GD2CART, as well as how well it works in treating patients with osteosarcoma or neuroblastoma that has come back…
- Conditions
- Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma
- Trial name
- NCT04539366
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 6 sites in United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Acute Lymphoblastic Leukemia
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
This is a pilot study of a drug called rituximab used together with other drugs-prednisone, etoposide, and ifosfamide. Prednisone, etoposide, and ifosfamide have been used as part of standard chemotherapy for relapsed Acute…
- Conditions
- Leukemia, Acute Lymphoblastic Leukemia, ALL
- Trial name
- Rituximab (NCT01230788)
- Testing
- rituximab
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Emory University
Cervical Intraepithelial Neoplasia, Uterine Neoplasms
A Trial for Patients With Advanced/Recurrent Cervical Cancer
This phase II trial is studying the antitumor activity of single agent pemetrexed 900mg/m2 IV over 10 minutes in patients with recurrent cervical cancer.
- Conditions
- Cervical Intraepithelial Neoplasia, Uterine Neoplasms, Genital Neoplasms, Female
- Trial name
- NCT00190983
- Testing
- Pemetrexed
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
This phase I trial tests the safety, side effects and best infusion dose of genetically engineered cells called anti-CD19/CD20/CD22 chimeric antigen receptor (CAR) T-cells following a short course of chemotherapy with…
- Conditions
- Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia
- Trial name
- NCT05418088
- Testing
- Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Sumithira Vasu
Acute Myeloid Leukemia
Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML
This project is a prospective, multicenter, randomized controlled clinical study. The subjects were refractory / relapsed AML patients aged ≤ 60 years diagnosed by bone marrow cell morphology, immunology, genetics and therapeutic…
- Trial name
- NCT06133556
- Testing
- MCBC regimen, Bu/Cy regimen
- Volunteers
- 237 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.